InvestorsHub Logo
Followers 41
Posts 19806
Boards Moderated 2
Alias Born 01/04/2011

Re: ysung post# 181

Thursday, 09/28/2023 6:31:46 PM

Thursday, September 28, 2023 6:31:46 PM

Post# of 249
Yet beginning three days later Symetryx sold all its shares of NBSE.

It seems Symetryx and the Neubase Board were unable to find or see eye to eye on a suitable merger candidate. Or something else that promoted a large active investor to sell its entire position.

Symetryx exits stake in NeuBase Therapeutics, shares fall
Sep. 19, 2023 2:03 PM ET
NeuBase Therapeutics, Inc. (NBSE)
By: Deepa Sarvaiya, SA News Editor

NeuBase Therapeutics (NASDAQ:NBSE) falls 14% after disclosing that Symetryx has sold its entire position in the biopharmaceutical company.
Symetryx sold 203,337 shares in the price range of $1.19-$1.44. Symetryx has sold 680,081 shares in the last 10 days.
According to the form 4 [Sept. 14th, 2023], Symetryx now beneficially owns no shares in the company.
As per the recent filing on Sept. 06, Symetryx acquired 20% stake in NeuBase.
https://seekingalpha.com/filing/7872032?hasComeFromMpArticle=false


Is today's higher action a bounce, or a facilitated bounce, or something real?

.

© 2023, by StockItOut

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBSE News